View in EDS HTML Full Text PDF Full Text

IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC.

Saved in:
Bibliographic Details
Title: IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC.
Authors: Cui, Yanan1 (AUTHOR), Qiu, Tianyu1 (AUTHOR), Wang, Jiale1 (AUTHOR), Liu, Xinyu1 (AUTHOR), Luo, Libo1 (AUTHOR), Yin, Jizhong1 (AUTHOR), Zhi, Xinxin1 (AUTHOR), Wang, Wanying1 (AUTHOR), Feng, Gaohua2 (AUTHOR), Wu, Chunyan3 (AUTHOR), Zhao, Zhikai3 (AUTHOR), Zhang, Hua4,5 (AUTHOR), Li, Fei6 (AUTHOR) li_fei@fudan.edu.cn, Wu, Fengying1 (AUTHOR) fywu@163.com, Ren, Shengxiang1 (AUTHOR) harry_ren@tongji.edu.cn
Source: Molecular Cancer. 7/3/2025, Vol. 24 Issue 1, p1-20. 20p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14764598
DOI:10.1186/s12943-025-02383-x